LGND
LIGAND PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$316.13
+0.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 253.8M | 268.1M | 167.1M | 131.3M | 196.2M |
| Cost of Revenue | (18.0M) | 6.6M | 11.1M | 35.0M | 52.8M |
| Gross Profit | 271.9M | 261.5M | 156.1M | 96.3M | 143.4M |
| Operating Expenses | |||||
| R&D Expense | 23.1M | 81.2M | 21.4M | 24.5M | 36.1M |
| SG&A Expense | 147.6M | 92.4M | 78.7M | 52.8M | 70.1M |
| General & Admin Expense | 147.6M | 92.4M | 78.7M | 52.8M | 70.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 70.9M | 40.7M | 78.6M | 7.0M | 34.2M |
| Total Operating Expenses | 241.6M | 214.3M | 178.7M | 84.3M | 140.4M |
| Cost and Expenses | 223.6M | 220.9M | 189.7M | 119.4M | 193.2M |
| Operating Income (EBIT) | 30.2M | 47.2M | (22.6M) | 11.9M | 3.0M |
| Non-Operating | |||||
| Interest Income | 22.9M | 13.7M | 8.1M | 7.7M | 2.0M |
| Interest Expense | 5.3M | 4.7M | 3.0M | 656.0K | 1.8M |
| Net Interest Income | 17.7M | 8.9M | 5.0M | 7.1M | 247.0K |
| Other Non-Op Income/Expense | 22.5M | 111.8M | 25.1M | 51.7M | 33.0M |
| Non-Operating Income (excl Interest) | (24.2M) | (111.8M) | (28.2M) | (52.4M) | (34.8M) |
| EBT (Pre-Tax Income) | 52.7M | 159.0M | 2.5M | 63.7M | 36.0M |
| Income Tax Expense | 1.3M | 34.5M | 6.5M | 9.8M | 41.2M |
| Bottom Line | |||||
| Net Income | 51.5M | 124.5M | (4.0M) | 52.2M | (33.4M) |
| Earnings from Cont. Ops | 51.5M | 124.5M | (4.0M) | 53.8M | (5.2M) |
| Earnings from Discont. Ops | — | — | — | (1.7M) | (28.1M) |
| Bottom Line Net Income | 51.5M | 124.5M | (4.0M) | 52.2M | (33.4M) |
| Per Share | |||||
| Basic EPS | $2.59 | $6.44 | ($0.22) | $3.02 | ($1.98) |
| Diluted EPS | $2.24 | $6.13 | ($0.22) | $2.94 | ($1.98) |
| Revenue Per Share | $12.72 | $13.86 | $9.14 | $7.59 | $11.63 |
| Shares | |||||
| Basic Shares Outstanding | 20.0M | 19.3M | 18.3M | 17.3M | 16.9M |
| Diluted Shares Outstanding | 20.0M | 20.3M | 18.3M | 17.8M | 16.9M |
| Profitability Metrics | |||||
| EBITDA | 80.5M | 192.7M | 40.8M | 100.8M | 81.2M |
| D&A | 26.1M | 33.8M | 35.2M | 36.5M | 43.4M |
| EBIT | 54.5M | 159.0M | 5.6M | 64.3M | 37.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026